Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE-EARLY: Subcutaneous belimumab in early systemic lupus erythematosus
jRCT2071240068Phase 4Recruiting
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by GSK. Primary endpoint: LLDAS at Week 52. Started Oct 2024; status: recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2071240068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240068.